<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="data-paper"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art560.dtd?><?SourceDTD.Version 5.6.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_DIB104372 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Data Brief</journal-id><journal-id journal-id-type="iso-abbrev">Data Brief</journal-id><journal-title-group><journal-title>Data in Brief</journal-title></journal-title-group><issn pub-type="epub">2352-3409</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6715830</article-id><article-id pub-id-type="publisher-id">S2352-3409(19)30726-7</article-id><article-id pub-id-type="doi">10.1016/j.dib.2019.104372</article-id><article-id pub-id-type="publisher-id">104372</article-id><article-categories><subj-group subj-group-type="heading"><subject>Biochemistry, Genetics and Molecular Biology</subject></subj-group></article-categories><title-group><article-title>RNA sequencing data of human prostate cancer cells treated with androgens</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Poluri</surname><given-names>Raghavendra Tejo Karthik</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Beauparlant</surname><given-names>Charles Joly</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Droit</surname><given-names>Arnaud</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Audet-Walsh</surname><given-names>&#x000c9;tienne</given-names></name><email>etienne.audet-walsh@chrchudequebec.ulaval.ca</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Department of Molecular Medicine, Faculty of Medicine, Universit&#x000e9; Laval, Axe Endocrinologie &#x02013; N&#x000e9;phrologie du Centre de recherche du CHU de Qu&#x000e9;bec &#x02013; Universit&#x000e9; Laval, Qu&#x000e9;bec City, Qu&#x000e9;bec, Canada</aff><aff id="aff2"><label>b</label>Centre de recherche sur le cancer de l'Universit&#x000e9; Laval, Qu&#x000e9;bec City, Qu&#x000e9;bec, Canada</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Department of Molecular Medicine, Faculty of Medicine, Universit&#x000e9; Laval, Axe Endocrinologie &#x02013; N&#x000e9;phrologie du Centre de recherche du CHU de Qu&#x000e9;bec &#x02013; Universit&#x000e9; Laval, Qu&#x000e9;bec City, Qu&#x000e9;bec, Canada. <email>etienne.audet-walsh@chrchudequebec.ulaval.ca</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>09</day><month>8</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>8</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>09</day><month>8</month><year>2019</year></pub-date><volume>25</volume><elocation-id>104372</elocation-id><history><date date-type="received"><day>24</day><month>4</month><year>2019</year></date><date date-type="rev-recd"><day>22</day><month>6</month><year>2019</year></date><date date-type="accepted"><day>1</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Author(s)</copyright-statement><copyright-year>2019</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>Prostate cancer (PCa) is the most frequent cancer in North American men and PCa cells rely on the androgen receptor (AR) for growth and survival. To understand the effect of AR in cancer cells, we have treated LNCaP and LAPC4 cells, two immortalized human PCa cells <italic>in&#x000a0;vitro</italic>, with the synthetic androgen R1881 and then performed RNA-seq analyses. High quality sequencing data have been analyzed using our bioinformatic pipeline which consists of FastQC for quality controls, Trimmomatic for trimming, and Kallisto for pseudoalignment to the transcriptome. Differentially expressed genes were identified using DESeq2 after adjustment for false-discovery rate (FDR <italic>q</italic> values&#x000a0;&#x0003c;&#x000a0;0.05) and Relative Log Expression (RLE) normalization. Gene Set Enrichment Analysis (GSEA) was also performed to identify biological pathways significantly modulated by androgens. GSEA analyses identified the androgen signaling pathway, as well as several metabolic pathways, as significantly enriched following androgen stimulation. These analyses highlight the most significant metabolic pathways up-regulated following AR activation. Raw and processed RNA-seq data were deposited and made publicly available on the Gene Expression Omnibus (GEO; GSE128749). These data have been incorporated in a recent article describing the functions of AR as a master regulator of PCa cell metabolism. For more details about interpretation of these results, please refer to &#x0201c;Functional genomics studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer&#x0201d; by Gonthier et&#x000a0;al. (doi: 10.1016/j.jsbmb.2019.04.016).</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Steroid</kwd><kwd>Nuclear receptor</kwd><kwd>Hormone receptor</kwd><kwd>Metabolism</kwd><kwd>Metabolic reprogramming</kwd><kwd>Castration-resistance</kwd><kwd>Mitochondria</kwd><kwd>Glycolysis</kwd><kwd>Fatty acid metabolism</kwd></kwd-group></article-meta></front><body><p id="p0010"><table-wrap position="float" id="undtbl1"><caption><p>Specifications Table</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Subject area</td><td>Cancer Research, Endocrinology, Androgen receptor</td></tr><tr><td>More specific subject area</td><td>Prostate Cancer, Molecular Biology, Bioinformatics, Cancer Genomics, Steroid, castration-resistant, androgen</td></tr><tr><td>Type of data</td><td><italic>Transcriptomic data</italic></td></tr><tr><td>How data was acquired</td><td>RNA-sequencing (125bp paired end sequencing using a HiSeq 2500)</td></tr><tr><td>Data format</td><td><italic>Raw and processed RNA-seq data. Raw data (FASTQ) and processed RNA-seq data, including TPM and FPKM values, are fully available.</italic></td></tr><tr><td>Experimental factors</td><td><italic>Cells were treated with</italic> 10nM <italic>of the synthetic androgen R1881 or vehicle (ethanol 96%)</italic></td></tr><tr><td>Experimental features</td><td><italic>Cells were seeded in RPMI 1640 media with no phenol red and containing 5% charcoal-stripped serum for 48h to allow steroid deprivation. Media was then changed, and fresh media with</italic> 10nM <italic>R1881 or vehicle (EtOH 96%) was added. After 24h treatment, cells were harvested and RNA was purified with RNeasy super purification kit from QIAGEN. RNA was then sent to the Genomic Centre of the Centre de recherche du CHU de Qu&#x000e9;bec - Universit&#x000e9; Laval for mRNA enrichment and RNA-sequencing. Standard protocol of NEBNext Ultra II Directional RNA library prep kit was followed for mRNA enrichment and library preparation.</italic></td></tr><tr><td>Data source location</td><td>Quebec City, Quebec, Canada</td></tr><tr><td>Data accessibility</td><td>Both raw and processed RNA-seq data were deposited on the Gene Expression Omnibus (GEO) and made publicly available (GSE128749). <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128749" id="intref0010">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128749</ext-link></td></tr><tr><td>Related research article</td><td>Functional genomics studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer by Gonthier et&#x000a0;al. (<ext-link ext-link-type="doi" xlink:href="10.1016/j.jsbmb.2019.04.016" id="intref0015">https://doi.org/10.1016/j.jsbmb.2019.04.016</ext-link>)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="undtbl2"><table frame="hsides" rules="groups"><tbody><tr><td><bold>Value of the data</bold><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0015">Bioinformatic analyses of differentially expressed genes and biological pathways regulated by androgens can be studied for a better understanding of the effect of AR in PCa.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0020">Validation in two distinct PCa cell lines allow for the identification of more reproducible results.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0025">These data highlight a new function of AR in PCa as a master regulator of cellular energy metabolism.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0030">These data may allow the discovery of new therapies targeting the unique PCa cell metabolic program.</p></list-item></list></td></tr></tbody></table></table-wrap></p><sec id="sec1"><label>1</label><title>Data</title><p id="p0035">The raw data (.fastq files) generated from Illumina sequencing were deposited on the Gene Expression Omnibus (GEO) with the reference number GSE128749 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128749" id="intref0020">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128749</ext-link>). The comma separated value files (.csv) which have been produced after the quantification and pseudoalignment with the transcriptome hg38 using Kallisto were also uploaded on GEO. These files contain the raw counts, the transcripts per million (TPM) values, and the fragments per kilobase million (FPKM) values for every sample. Differentially expressed genes on normalized data were identified using a FDR <italic>q</italic> value&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec><sec id="sec2"><label>2</label><title>Experimental design, materials, and methods</title><sec id="sec2.1"><label>2.1</label><title>Cells</title><p id="p0040">LNCaP and LAPC4, two androgen receptor (AR) positive human PCa cell lines, were initially obtained from the ATCC and re-authentified in 2016 <xref rid="bib1" ref-type="bibr">[1]</xref>. After resuscitation, the cells were not kept in culture for more than 3 months. Cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), streptomycin, penicillin, and sodium pyruvate in 37&#x000a0;&#x000b0;C incubators with 5% CO<sub>2</sub>. Before androgen stimulation, cells were trypsinized and seeded at a 70% confluence in RPMI-1640 media with no phenol-red and supplemental with 5% charcoal-stripped serum (CSS), streptomycin, penicillin, and sodium pyruvate, as described previously <xref rid="bib2" ref-type="bibr">[2]</xref>. After hormonal deprivation (48h), media was changed and fresh media containing 10nM of the synthetic androgen R1881 or vehicle (EtOH 96%). 24h later, cells were harvested for RNA purification using the RNA purification kit RNeasy plus mini kit from QIAGEN.</p></sec><sec id="sec2.2"><label>2.2</label><title>Sequencing</title><p id="p0045">Excellent RNA integrity was confirmed using a TapeStation 2200 (Agilent); all samples had an RNA integrity number equivalent (RIN<sup>e</sup>)&#x000a0;&#x0003e;&#x000a0;8.5. mRNA enrichment and library preparation were performed using the NEBNext Ultra II Directional RNA library prep kit following the manufacturer's protocol. RNA was then sent to the Genomic Centre of the Centre de recherche du CHU de Qu&#x000e9;bec - Universit&#x000e9; Laval for sequencing using a HiSeq 2500 (125bp paired-end sequencing).</p></sec><sec id="sec2.3"><label>2.3</label><title>RNA-seq analysis</title><p id="p0050">After sequencing, raw data were obtained in the fastq format. FastQC <xref rid="bib3" ref-type="bibr">[3]</xref> was used for validating the quality of the data. Trimming of the adaptor content and over-represented sequences was performed using Trimmomatic <xref rid="bib4" ref-type="bibr">[4]</xref>. Also note that trimming was performed with the minimal length (MINLEN) set at 36. Quality check using FastQC was performed again on the trimmed sequences (<xref rid="tbl1" ref-type="table">Table 1</xref>). For the pseudoalignment of the trimmed sequences to the hg38 transcriptome, the Kallisto tool was used <xref rid="bib5" ref-type="bibr">[5]</xref>. Final normalization was performed using the Relative Log Expression (RLE) method <xref rid="bib6" ref-type="bibr">[6]</xref>. We have used the R-package called Tximport to convert the transcript quantifications to gene quantifications <xref rid="bib7" ref-type="bibr">[7]</xref>.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Number of reads for raw and trimmed sequences of PCa cells treated with androgens.</p></caption><alt-text id="alttext0015">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Cell lines</th><th>Treatment</th><th>Reads (Raw)</th><th>Reads (after trimming)</th></tr></thead><tbody><tr><td rowspan="6">LNCaP</td><td>Control #1</td><td>9327182</td><td>7694732</td></tr><tr><td>Control #2</td><td>11058265</td><td>9014786</td></tr><tr><td>Control #3</td><td>10258931</td><td>8909738</td></tr><tr><td>R1881 #1</td><td>7812714</td><td>6616969</td></tr><tr><td>R1881 #2</td><td>9964804</td><td>8508748</td></tr><tr><td>R1881 #3</td><td>10496859</td><td>8965255</td></tr><tr><td rowspan="5">LAPC4</td><td>Control #1</td><td>8744802</td><td>7390781</td></tr><tr><td>Control #2</td><td>6528343</td><td>5443146</td></tr><tr><td>Control #3</td><td>10146342</td><td>8641030</td></tr><tr><td>R1881 #1</td><td>9384625</td><td>7940193</td></tr><tr><td>R1881 #2</td><td>11134285</td><td>9474978</td></tr></tbody></table></table-wrap></p></sec><sec id="sec2.4"><label>2.4</label><title>Differential gene expression and GSEA analysis</title><p id="p0055">To study genes regulated by AR in PCa cells, differential expressed genes were identified using a FDR <italic>q</italic> value&#x000a0;&#x0003c;&#x000a0;0.05 with DESeq2 <xref rid="bib8" ref-type="bibr">[8]</xref>. Overall, 1868 and 716 genes were up-regulated in LNCaP and LAPC4 cells and 2294 and 847 genes were significantly down-regulated in LNCaP and LAPC4 cells, respectively (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>A). Of these, 321 common genes were up-regulated while 314 common genes were down-regulated in both cell lines (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>B). GSEA analyses <xref rid="bib9" ref-type="bibr">[9]</xref> were also performed using TPM values to identify the most significantly up-regulated pathways following activation of AR in these human PCa cells. In both cell lines, the androgen signaling pathway was highly enriched following R1881 treatment (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>C). In addition, several metabolic pathways were also enriched in both LNCaP and LAPC4 cells following AR activation (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>D).<fig id="fig1"><label>Fig.&#x000a0;1</label><caption><p>Transcriptomic analyses of the androgen signaling pathway functions in human prostate cancer cells. A) Number of genes significantly up- or down-regulated following treatment with R1881 in LNCaP and LAPC4 cells. A FDR <italic>q</italic> value&#x000a0;&#x0003c;&#x000a0;0.05 was used to identify differentially expressed genes. B) Venn diagrams showing the overlap between genes up-regulated (left) and down-regulated (right) by R1881 in LNCaP and LAPC4 cells. C) Gene set enrichment analysis (GSEA) plots for the &#x0201c;Hallmarks - Androgen Response&#x0201d; signature in LNCaP and LAPC4 cells. NES: normalized enrichment score. D) GSEA signatures enrichment scores for significantly enriched metabolic pathways in LNCaP and LAPC4 cells following 24h treated with R1881. OXPHOS: oxidative phosphorylation (mitochondrial respiration) *<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05; **<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01; ***<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001.</p></caption><alt-text id="alttext0010">Fig.&#x000a0;1</alt-text><graphic xlink:href="gr1"/></fig></p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Audet-Walsh</surname><given-names>E.</given-names></name></person-group><article-title>Androgen-dependent repression of ERRgamma reprograms metabolism in prostate cancer</article-title><source>Cancer Res.</source><volume>77</volume><issue>2</issue><year>2017</year><fpage>378</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">27821488</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Audet-Walsh</surname><given-names>E.</given-names></name></person-group><article-title>Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer</article-title><source>Genes Dev.</source><volume>31</volume><issue>12</issue><year>2017</year><fpage>1228</fpage><lpage>1242</lpage><pub-id pub-id-type="pmid">28724614</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="book" id="sref3"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>S.</given-names></name></person-group><chapter-title>FastQC A Quality Control Tool for High Throughput Sequence Data</chapter-title><year>2010</year><comment>Available from:</comment><ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/" id="intref0025">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>A.M.</given-names></name><name><surname>Lohse</surname><given-names>M.</given-names></name><name><surname>Usadel</surname><given-names>B.</given-names></name></person-group><article-title>Trimmomatic: a flexible trimmer for Illumina sequence data</article-title><source>Bioinformatics</source><volume>30</volume><issue>15</issue><year>2014</year><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="pmid">24695404</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>N.L.</given-names></name></person-group><article-title>Near-optimal probabilistic RNA-seq quantification</article-title><source>Nat. Biotechnol.</source><volume>34</volume><issue>5</issue><year>2016</year><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">27043002</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S.</given-names></name></person-group><article-title>Count-based differential expression analysis of RNA sequencing data using R and Bioconductor</article-title><source>Nat. Protoc.</source><volume>8</volume><issue>9</issue><year>2013</year><fpage>1765</fpage><lpage>1786</lpage><pub-id pub-id-type="pmid">23975260</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Soneson</surname><given-names>C.</given-names></name><name><surname>Love</surname><given-names>M.I.</given-names></name><name><surname>Robinson</surname><given-names>M.D.</given-names></name></person-group><article-title>Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences</article-title><source>F1000 Res</source><volume>4</volume><year>2015</year><fpage>1521</fpage></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Love</surname><given-names>M.I.</given-names></name><name><surname>Huber</surname><given-names>W.</given-names></name><name><surname>Anders</surname><given-names>S.</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol.</source><volume>15</volume><issue>12</issue><year>2014</year><fpage>550</fpage><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Mootha</surname><given-names>V.K.</given-names></name></person-group><article-title>PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes</article-title><source>Nat. Genet.</source><volume>34</volume><issue>3</issue><year>2003</year><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">12808457</pub-id></element-citation></ref></ref-list><sec id="appsec1"><title>Conflict of Interest</title><p id="p0065">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec><ack id="ack0010"><title>Acknowledgments</title><p>This work was supported by funding to EAW from the <funding-source id="gs1">Cancer Research Society</funding-source> and the <funding-source id="gs2">Canadian Institutes of Health Research</funding-source> (CIHR; 23123) and the <funding-source id="gs3">CIHR</funding-source> (PJT159530).</p></ack></back></article>